NeuroEbola

NeuroEbola synthesizes current knowledge about the neurological, neuropsychiatric and cognitive consequences experienced by survivors of Ebola virus disease and frames key priorities for longitudinal research and clinical follow-up. Drawing on documented mortality ranges for different ebolavirus species and recent therapeutic advances, the chapter highlights that despite improvements in survival—most notably during the North Kivu outbreak where monoclonal antibodies and antiviral regimens improved survival rates to approximately 80 percent—survivors continue to manifest a spectrum of neurologic and psychiatric complications. These include seizures, memory impairment, persistent headaches, cranial nerve dysfunction, tremors, and ocular complications affecting up to a third of examined subjects, alongside elevated rates of depression, anxiety, and post-traumatic stress disorder. The authors emphasize that cognitive screening tools such as the Mini-Mental State Examination have detected lower scores during the acute stage among survivors, pointing to early neurocognitive impact that may persist or evolve. Variation in psychiatric outcomes by sex and by severity of the acute illness is noted, underscoring the need to disaggregate findings by demographic and clinical variables to better define risk groups and tailor interventions.

The chapter situates these clinical observations within the broader implications for long-term care and research design. NeuroEbola calls for systematic, longitudinal assessments of survivors to capture acute, chronic, and delayed-onset manifestations of neurological and neuropsychiatric disease. The authors argue that improvements in survival due to therapeutics like ansuvimab (mAb114/Ebanga) and REGN-EB3 (Inmazeb) produce a growing population of survivors who require structured follow-up to identify and address persistent deficits that can impair functioning and quality of life. The text underscores the multidimensional burden of post-Ebola sequelae—neurologic symptoms that may be directly virus-related or immune-mediated, neuropsychiatric conditions potentially linked to the traumatic context of disease and care, and cognitive impairments that affect daily living and rehabilitation potential. Because manifestations vary in timing and severity, NeuroEbola advocates integrated clinical pathways combining neurology, psychiatry, ophthalmology, neuropsychology, and rehabilitation services for comprehensive evaluation and management.

Research priorities outlined include standardized cognitive and psychiatric assessment batteries, biomarker and neuroimaging studies to characterize pathophysiology, and epidemiologic work to quantify prevalence and predictors of long-term outcomes across diverse outbreak settings. The chapter also highlights the importance of sex-specific analyses and correlates of acute disease severity to inform targeted interventions. With an eye toward practice and policy, NeuroEbola calls for health systems in affected regions to prepare for sustained survivor care needs and for international research collaborations to generate evidence that can inform clinical guidelines and resource allocation. NeuroEbola as a pressing public health and clinical concern, linking improved survival to an urgent obligation to understand and ameliorate long-term neurological and psychiatric consequences among survivors.